Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

We have recently downgraded SurModics Inc. (SRDX - Analyst Report) to Neutral from Outperform with a target price of $16.00.

In November 2011, Surmodics sold the assets of the Pharmaceuticals division to Germany’s Evonik Industries AG for $30 million cash. The deal enables the company to focus extensively on its Medical Device and In Vitro Diagnostics units and also strengthens its balance sheet. Even though we are positive on SurModics’ move to sell its Pharmaceuticals unit we prefer to adopt a wait-and-see stance until the move yields the desired results.

We are also concerned about factors such as partner Johnson & Johnson’s (JNJ - Analyst Report) decision to stop manufacturing Cypher and Cypher Select Plus sirolimus-eluting coronary stents. SurModics received royalties on sales of the product. Setbacks of similar nature will negatively impact SurModics stock price.

We remind investors that SurModics has taken a number of steps following its disappointing showing in fiscal 2010. In August 2011, with a view to optimizing its resources and maximizing long-term growth potential, SurModics announced that it will its trim work-force by 9%. Earlier in October 2010, SurModics trimmed its work-force by 13% and made certain changes to its organizational structure.

Moreover, following the disappointing performance in fiscal 2010, SurModics revamped its board of directors and also brought about a change at its helm, with the appointment of a new CEO, Gary R. Maharaj. We note that Maharaj is the former President and CEO of Arizant Inc., which was sold to 3M Company (MMM - Analyst Report) in October 2010. However, if the moves fail to deliver the desired results then the stock will be negatively impacted.

In view of the above uncertainties, we see limited upside potential for the stock from current levels. Consequently we have reverted to a Neutral stance on SurModics.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%